As of 2024-12-13, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 76.45 mil USD. INO's TTM EBITDA according to its financial statements is -119.63 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 14.7x - 17.0x | 16.0x |
| Forward P/E multiples | 15.4x - 21.2x | 15.7x |
| Fair Price | (69.76) - (76.91) | (71.82) |
| Upside | -1955.2% - -2145.4% | -2010.1% |
| Date | EV/EBITDA |
| 2024-12-10 | -0.70 |
| 2024-12-09 | -0.72 |
| 2024-12-06 | -0.73 |
| 2024-12-05 | -0.70 |
| 2024-12-04 | -0.72 |
| 2024-12-03 | -0.74 |
| 2024-12-02 | -0.77 |
| 2024-11-29 | -0.76 |
| 2024-11-27 | -0.73 |
| 2024-11-26 | -0.69 |
| 2024-11-25 | -0.72 |
| 2024-11-22 | -0.71 |
| 2024-11-21 | -0.70 |
| 2024-11-20 | -0.68 |
| 2024-11-19 | -0.70 |
| 2024-11-18 | -0.71 |
| 2024-11-15 | -0.75 |
| 2024-11-14 | -0.86 |
| 2024-11-13 | -0.90 |
| 2024-11-12 | -0.94 |
| 2024-11-11 | -0.98 |
| 2024-11-08 | -1.03 |
| 2024-11-07 | -1.02 |
| 2024-11-06 | -1.06 |
| 2024-11-05 | -1.04 |
| 2024-11-04 | -1.02 |
| 2024-11-01 | -1.01 |
| 2024-10-31 | -0.97 |
| 2024-10-30 | -1.03 |
| 2024-10-29 | -1.03 |
| 2024-10-28 | -1.06 |
| 2024-10-25 | -1.04 |
| 2024-10-24 | -1.05 |
| 2024-10-23 | -1.06 |
| 2024-10-22 | -1.06 |
| 2024-10-21 | -1.07 |
| 2024-10-18 | -1.04 |
| 2024-10-17 | -1.06 |
| 2024-10-16 | -1.07 |
| 2024-10-15 | -1.04 |
| 2024-10-14 | -1.06 |
| 2024-10-11 | -1.07 |
| 2024-10-10 | -1.00 |
| 2024-10-09 | -1.02 |
| 2024-10-08 | -1.06 |
| 2024-10-07 | -0.98 |
| 2024-10-04 | -1.03 |
| 2024-10-03 | -1.05 |
| 2024-10-02 | -1.05 |
| 2024-10-01 | -1.04 |